Bristol-Myers Squibb Stock Discussion

$Verizon(VZ.US)$ $Cadence Design Systems(CDNS.US)$ $NXP Semiconductors(NXPI.US)$ $Coca-Cola(KO.US)$ $GE Aerospace(GE.US)$ $Spotify Technology(SPOT.US)$ $Alphabet-A(GOOGL.US)$ $Tesla(TSLA.US)$ $Visa(V.US)$ $Texas Instruments(TXN.US)$ $Vertiv Holdings(VRT.US)$ $ServiceNow(NOW.US)$ $KLA Corp(KLAC.US)$ $IBM Corp(IBM.US)$ $Chipotle Mexican Grill(CMG.US)$ $Ford Motor(F.US)$ $AbbVie(ABBV.US)$ $American Airlines(AAL.US)$ $British American Tobacco(BTI.US)$ $Bristol-Myers Squibb(BMY.US)$ $3M(MMM.US)$
📊⚡️📊

Dividend stocks haven't been taking off these days, and that's in part due to high interest rates. When investors can get healthy returns from low-risk, interest-paying assets, the case for buying dividend stocks is naturally less appealing. But the good news for long-term investors is that this means stock prices for some solid dividend stocks are low, and there are some enticing deals available right now.
Bristol Myers Squibb $Bristol-Myers Squibb(BMY.US)$ , Cisco S...

$Bristol-Myers Squibb(BMY.US)$
good news with share drops doent understand this share.

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...

$Viking Therapeutics(VKTX.US)$ : “I’m a Lilly guy...To go up against Lilly is very, very hard.”
$CAVA Group(CAVA.US)$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US)$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US)$ : “There’s g...

$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Harmony Biosciences(HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US)$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)

Background and Recent Performance
$Bristol-Myers Squibb(BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US)$
Despite recent performance s...

$Bristol-Myers Squibb(BMY.US)$
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates